The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Kinetic Studies of Amyloid β-Protein Fibril Assembly
Open accessAbstract
Amyloid beta-protein (Abeta) fibril assembly is a defining characteristic of Alzheimer's disease. Fibril formation is a complex nucleation-dependent polymerization process characterized in vitro by an initial lag phase. To a significant degree, this phase is a consequence of the energy barrier that must be overcome in order for Abeta monomers to fold and oligomerize into fibril nuclei. Here we show that low concentrations of 2,2,2-trifluoroethanol (TFE) convert predominately unstructured Abeta monomers into partially ordered, quasistable conformers. Surprisingly, this results in a temporal decrease in the lag phase for fibril formation and a significant increase in the rate of fibril elongation. The TFE effect is concentration dependent and is maximal at approximately 20% (v/v). In the presence of low concentrations of TFE, fibril formation is observed in Abeta samples at nanomolar concentration, well below the critical concentration for Abeta fibril formation in the absence of TFE. As the amount of TFE is increased above 20%, helix content progressively rises to approximately 80%, a change paralleled first by a decrease in elongation rate and then by a complete cessation of fibril growth. These findings are consistent with the hypothesis that a partially folded helix-containing conformer is an intermediate in Abeta fibril assembly. The requirement that Abeta partially folds in order to assemble into fibrils contrasts with the mechanism of amyloidogenesis of natively folded proteins such as transthyretin and lysozyme, in which partial unfolding is a prerequisite. Our results suggest that in vivo, factors that affect helix formation and stability will have significant effects on the kinetics of Abeta fibril formation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
From Levinthal to pathways to funnels
Dill, K. A., & Chan, H. S. (1997) · Nature Structural & Molecular Biology · doi:10.1038/nsb0197-10 · Cited by 2,293
Protein misfolding, evolution and disease
Dobson, C. M. (1999) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(99)01445-0 · Cited by 1,952
Amyloid Deposits and Amyloidosis: The β-Fibrilloses(First of Two Parts)
Glenner, G. G. (1980) · New England Journal of Medicine · doi:10.1056/nejm198006053022305 · Cited by 1,790
Santoro, M. M., & Bolen, D. W. (1988) · Biochemistry · doi:10.1021/bi00421a014 · Cited by 1,582
Amyloid β-Protein Fibrillogenesis
Walsh, D. M., Lomakin, A., Benedek, G. B., Condron, M. M., & Teplow, D. B. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.35.22364 · Cited by 1,145
Self-citationEvidence for a Partially Folded Intermediate in α-Synuclein Fibril Formation
Uversky, V. N., Li, J., & Fink, A. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010907200 · Cited by 1,096
Review: History of the Amyloid Fibril
Sipe, J. D., & Cohen, A. S. (2000) · Journal of Structural Biology · doi:10.1006/jsbi.2000.4221 · Cited by 1,054
Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis
Booth, D. R., Sunde, M., Bellotti, V., Robinson, C. V., Hutchinson, W. L., Fraser, P. E., Hawkins, P. N., Dobson, C. M., Radford, S. E., Blake, C. C. F., et al. (1997) · Nature · doi:10.1038/385787a0 · Cited by 1,048
Amyloid β-Protein Fibrillogenesis
Walsh, D. M., Hartley, D. M., Kusumoto, Y., Fezoui, Y., Condron, M. M., Lomakin, A., Benedek, G. B., Selkoe, D. J., & Teplow, D. B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.36.25945 · Cited by 1,046
Self-citationDesigning conditions for in vitro formation of amyloid protofilaments and fibrils
Chiti, F., Webster, P., Taddei, N., Clark, A., Stefani, M., Ramponi, G., & Dobson, C. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3590 · Cited by 1,039
Cited by
Protein Misfolding, Functional Amyloid, and Human Disease
Chiti, F., & Dobson, C. M. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.101304.123901 · Cited by 6,423
Maiti, N. C., Apetri, M. M., Zagorski, M. G., Carey, P. R., & Anderson, V. E. (2004) · Journal of the American Chemical Society · doi:10.1021/ja0356176 · Cited by 515
ThT 101: a primer on the use of thioflavin T to investigate amyloid formation
Gade Malmos, K., Blancas-Mejia, L. M., Weber, B., Buchner, J., Ramirez-Alvarado, M., Naiki, H., & Otzen, D. (2017) · Amyloid · doi:10.1080/13506129.2017.1304905 · Cited by 445
Tomaselli, S., Esposito, V., Vangone, P., van Nuland, N. A. J., Bonvin, A. M. J. J., Guerrini, R., Tancredi, T., Temussi, P. A., & Picone, D. (2006) · ChemBioChem · doi:10.1002/cbic.200500223 · Cited by 438
A partially folded structure of amyloid-beta(1–40) in an aqueous environment
Vivekanandan, S., Brender, J. R., Lee, S. Y., & Ramamoorthy, A. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.06.133 · Cited by 432
Misfolded proteins in Alzheimer's disease and type II diabetes
DeToma, A. S., Salamekh, S., Ramamoorthy, A., & Lim, M. H. (2012) · Chem. Soc. Rev. · doi:10.1039/c1cs15112f · Cited by 361
Bartolini, M., Bertucci, C., Bolognesi, M. L., Cavalli, A., Melchiorre, C., & Andrisano, V. (2007) · ChemBioChem · doi:10.1002/cbic.200700427 · Cited by 348
Implications of peptide assemblies in amyloid diseases
Ke, P. C., Sani, M.-A., Ding, F., Kakinen, A., Javed, I., Separovic, F., Davis, T. P., & Mezzenga, R. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00372b · Cited by 338
Prediction of the Absolute Aggregation Rates of Amyloidogenic Polypeptide Chains
DuBay, K. F., Pawar, A. P., Chiti, F., Zurdo, J., Dobson, C. M., & Vendruscolo, M. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.06.043 · Cited by 318
Conserved and Cooperative Assembly of Membrane-Bound α-Helical States of Islet Amyloid Polypeptide
Knight, J. D., Hebda, J. A., & Miranker, A. D. (2006) · Biochemistry · doi:10.1021/bi060579z · Cited by 309
Curcumin Modulates α-Synuclein Aggregation and Toxicity
Singh, P. K., Kotia, V., Ghosh, D., Mohite, G. M., Kumar, A., & Maji, S. K. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn3001203 · Cited by 307
Resveratrol inhibits beta-amyloid oligomeric cytotoxicity but does not prevent oligomer formation
Feng, Y., Wang, X.-P., Yang, S.-G., Wang, Y.-J., Zhang, X., Du, X.-T., Sun, X.-X., Zhao, M., Huang, L., & Liu, R.-T. (2009) · NeuroToxicology · doi:10.1016/j.neuro.2009.08.013 · Cited by 295
Life on the edge: a link between gene expression levels and aggregation rates of human proteins
Tartaglia, G. G., Pechmann, S., Dobson, C. M., & Vendruscolo, M. (2007) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2007.03.005 · Cited by 289
Faller, P. (2009) · ChemBioChem · doi:10.1002/cbic.200900321 · Cited by 285
Nanga, R. P. R., Brender, J. R., Vivekanandan, S., & Ramamoorthy, A. (2011) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2011.06.012 · Cited by 278
Amyloid β-protein oligomers and Alzheimer’s disease
Hayden, E. Y., & Teplow, D. B. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt226 · Cited by 276
Self-citationThe aggregation kinetics of Alzheimer's β‐amyloid peptide is controlled by stochastic nucleation
Hortschansky, P., Schroeckh, V., Christopeit, T., Zandomeneghi, G., & Fändrich, M. (2005) · Protein Science · doi:10.1110/ps.041266605 · Cited by 268
Neurotoxic protein oligomers — what you see is not always what you get
Bitan, G., Fradinger, E. A., Spring, S. M., & Teplow, D. B. (2005) · Amyloid · doi:10.1080/13506120500106958 · Cited by 221
Self-citation
Metadata
- Authors
- Fezoui, Y., & Teplow, D. B.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2002-10
- Volume
- 277
- Issue
- 40
- Pages
- 36948-36954
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1979509752
- Cited by
- 342
- References
- 49
- FWCI
- 8.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.